CX-2043 / CytomX, AbbVie - LARVOL DELTA

CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update (CytomX Press Release) - "Anticipated Events: Report initial data from the praluzatamab ravtansine (CX-2009) Phase 2 study in the fourth quarter of 2021. Report initial data from the CX-2029 Phase 2 expansion study in the fourth quarter of 2021. Submit IND applications for CX-2043 and CX-904 in late 2021. Virtual analyst and investor briefing with Key Opinion Leaders in April 2021 to discuss our Probody technology platform with focus on praluzatamab ravtansine and CX-2029."

Clinical • IND • P2 data • Diffuse Large B Cell Lymphoma • Esophageal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Solid Tumor

CytomX Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) - “In particular, CytomX expects to use the net proceeds, together with existing cash resources, to fund: (i) the advancement and expansion of the clinical development program for CX-2009, including the ongoing Phase 2 study of CX-2009 as monotherapy and in combination with CX-072 in breast cancer; (ii) the advancement and expansion of the clinical development program for CX-2029, including the ongoing Phase 2 study of CX-2029 in four types of cancer; (iii) IND enabling studies for CX-2043 and CX-904, their IND submissions and Phase 1 clinical development…”

Commercial • Breast Cancer • Oncology

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update (GlobeNewswire) - "...in the fourth quarter of 2020...This Phase 2 study is expected to be comprised of three arms. Arm A will enroll patients with hormone receptor (ER, PR) positive, HER2 non-amplified breast cancer for treatment with CX-2009 monotherapy (7mg/kg, q3w). Arm B will enroll patients with triple negative breast cancer (TNBC) for treatment with CX-2009 monotherapy (7mg/kg, q3w). Arm C will enroll patients with TNBC for treatment with CX-2009 monotherapy (7mg/kg q3w) in combination with CX-072 (pacmilimab, 1200mg q3w), the Company’s proprietary anti-PD-L1 Probody therapeutic candidate....CytomX presented updated preclinical data at the 32nd EORTC-NCI-AACR Symposium for CX-2043, a Probody Drug Conjugate targeting EpCAM (Epithelial Cell Adhesion Molecule)....CytomX is advancing CX-2043 towards clinical studies with IND filing projected for late 2021."

Enrollment status • IND • Breast Cancer • HER2 Positive Breast Cancer • Oncology • Triple Negative Breast Cancer